Advertisement
News
Subscribe to MDT Magazine News

Life Technologies Develops Fast and Accurate Test to Detect Europe's Deadly E. coli

June 6, 2011 3:32 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., June 6, 2011 /- Life Technologies Corporation (NASDAQ: LIFE ) today announced that it has developed a custom test (assay) to accurately detect the E. coli bacterium that has killed at least 22 people and affected more than 2,100 worldwide, including four new cases...

TOPICS:

Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resi...

June 5, 2011 11:35 pm | by Bio-Medicine.Org | Comments

WAYNE, N.J., June 6, 2011 /- Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA ( AL pharadin in SYM ptomatic P rostate CA ncer) trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in...

TOPICS:

ZALTRAPâ„¢ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients

June 5, 2011 11:35 pm | by Bio-Medicine.Org | Comments

PARIS and TARRYTOWN, N.Y., June 6, 2011 /- Sanofi (EURONEXT: SAN and NYSE: SNY ) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in...

TOPICS:
Advertisement

Keeping Neurons Alive in Parkinson's Patients

June 5, 2011 8:34 pm | by Massachusetts Institute of Technology | Comments

An upcoming clinical trial will attempt to solve problems that have plagued one potentially promising treatment.

Great Comebacks® Program Recognizes WOC Nurse Heidi H. Cross at WOCN 43rd Annual Conference

June 5, 2011 9:35 am | by Bio-Medicine.Org | Comments

NEW ORLEANS, June 5, 2011 /- Heidi H. Cross, RN, MSN, FNP-BC, CWOCN was presented with the 2011 WOC Nurse Great Comebacks® Award at the opening ceremony of the Wound, Ostomy and Continence Nurses (WOCN) Society's 43rd Annual Conference in New Orleans, LA. The Great Comebacks®...

TOPICS:

MIMcloud 2.0, Cloud Computing for Medical Images, Shown at SIIM 2011

June 5, 2011 8:33 am | by Diagnostic Imaging | Comments

(Press Release) MIM Software is currently demonstrating MIMcloud 2.0 at their booth (#725/727) at the 2011 SIIM conference in Washington, D.C.

TOPICS:

Great Comebacks® Program Recognizes National Award Winners

June 5, 2011 8:32 am | by Bio-Medicine.Org | Comments

NEW ORLEANS, June 5, 2011 /- Chuck Wielgus, Executive Director of USA Swimming, was named this year's Great Comebacks® National Award recipient at a ceremony held in conjunction with the Wound, Ostomy and Continence Nurses (WOCN) Society's 43rd Annual Conference in New Orleans, LA....

TOPICS:

NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®

June 5, 2011 5:34 am | by Bio-Medicine.Org | Comments

CHICAGO, June 5, 2011 /- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.  A total of 33 women in the study...

TOPICS:
Advertisement

New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening

June 5, 2011 5:31 am | by Bio-Medicine.Org | Comments

INDIANAPOLIS, June 5, 2011 /- Eli Lilly and Company (NYSE: LLY ) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is...

Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims

June 4, 2011 1:32 pm | by Bio-Medicine.Org | Comments

SWIFTWATER, Pa., June 4, 2011 /- Four-time NASCAR Cup Series champion Jeff Gordon, known as much for his prowess on the track as he is for his philanthropic activities and tireless support of critically ill children, has pledged his support of the Alabama tornado relief effort through the...

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meetin...

June 4, 2011 11:34 am | by Bio-Medicine.Org | Comments

CHICAGO and SAN FRANCISCO, June 4, 2011 /- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society...

Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 4, 2011 9:34 am | by Bio-Medicine.Org | Comments

CHICAGO, June 4, 2011 /- Genomic Health, Inc. (Nasdaq: GHDX ) today announced results of ten studies being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, including a second large validation study confirming the performance of the Onco type DX® colon...

TOPICS:

Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy

June 4, 2011 8:33 am | by Bio-Medicine.Org | Comments

SAN DIEGO, June 4, 2011 /- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial...

TOPICS:

Ariad reports positive Phase 1 data for leukemia drug

June 3, 2011 6:34 pm | by Mass High Tech: The Journal of New England Technology | Comments

Ariad Pharmaceuticals Inc. reported initial clinical results for its drug for advanced acute myeloid leukemia (AML), and is now planning the next steps to clinically develop ponatinib.

Boston Sci Recalls Catheters After Tip Detachments

June 3, 2011 6:34 pm | by U.S. Food & Drug Administration | Comments

Boston Scientific is conducting a Class I recall of its iCross catheters after several instances of the coronary imaging devices malfunctioning during intravascular ultrasound (IVUS) imaging.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading